MXCT实时信号 | 通过Getagraph.com最大化利润

购买 136948 min ago

@ $4.78

发出时间: 15 Feb 2024 @ 01:00

回报率: -2.30%

上一信号: Feb 13 - 23:49

上一信号: 出售

回报率: -0.46 %

Live Chart Being Loaded With Signals

Commentary (18 May 2024 @ 04:00):

Stats
今日成交量	270 413
平均成交量	560 692
市值	488.22M
EPS	$0 ( 2024-05-08 )
下一个收益日期	( $0 ) 2024-08-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-13.34
ATR14	$0.00800 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-26	Johnston John Joseph	Buy	5 000	Common Stock
2024-03-26	Johnston John Joseph	Sell	5 000	Common Stock
2024-03-26	Johnston John Joseph	Sell	5 000	Stock Option (right to buy)
2024-03-15	Ross Thomas M.	Buy	100 000	Employee Stock Option (right to buy)
2024-03-15	Ross Thomas M.	Buy	25 000	Common Stock

INSIDER POWER
40.30
Last 100 transactions
Buy: 1 609 082 \| Sell: 743 053

音量相关性

長: -0.32 (neutral)

短: -0.57 (weak negative)

Signal:(26.684) Neutral

MaxCyte, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

MaxCyte, Inc. 相关性 - 货币/商品

-0.15
( neutral )

0.19
( neutral )

0.00
( neutral )

-0.08
( neutral )

0.00
( neutral )

-0.30
( neutral )

MaxCyte, Inc. 财务报表

Annual	2023
营收:	$41.29M
毛利润:	$32.56M (78.86 %)
EPS:	$-0.370

FY	2023
营收:	$41.29M
毛利润:	$32.56M (78.86 %)
EPS:	$-0.370

FY	2022
营收:	$44.26M
毛利润:	$39.16M (88.48 %)
EPS:	$-0.190

FY	2021
营收:	$33.89M
毛利润:	$30.25M (89.24 %)
EPS:	$-0.210

Financial Reports:

No articles found.

MaxCyte, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

MaxCyte, Inc.

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.